LONG-TERM EFFICACY OF FLUOCINOLONE IN EYES WITH IRIS-LENS DIAPHRAGM DISRUPTION AND PCME WITH MEDICATION FIXED IN THE SCLERA (MEFISTO).
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
25
3
2022
medline:
23
6
2022
entrez:
24
3
2022
Statut:
ppublish
Résumé
The aim of our prospective off-label, interventional clinical trial was to evaluate the efficacy and safety of the fluocinolone-loop-anchoring technique over two years in eyes with iris-lens diaphragm disruption and pseudophakic cystoid macular edema. In 10 eyes, scleral fixation of fluocinolone implant was performed. Main outcome measures were the development of best-corrected visual acuity (BCVA), central retinal thickness over 24 months, and general safety of the procedure. A significant improvement to 0.57 ± 0.38 log MAR (Snellen 20/80) (range 0-1.30) was observed (P = 0.003) at 1 month. Further improvement to 0.45 ± 036 log MAR (Snellen 20/60) was observed until month 18 (P = 0.081). Mean central retinal thickness decreased by 22% from 601.6 ± 235.5 µm to 449.1 ± 128.9 µm at 1 month. In one patient, the implant has to be removed at Month 7 because of elevated intraocular pressure and one patient after globe rupture had a retinal redetachment at Month 4. In this study, we showed that the treatment of recalcitrant pseudophakic cystoid macular edema with scleral fixated fluocinolone implant in eyes with disruption of the iris-lens diaphragm provides good anatomical and functional results with a reasonable safety profile over 24 months in eyes where pseudophakic cystoid macular edema is otherwise difficult to treat and often left untreated.
Identifiants
pubmed: 35321998
doi: 10.1097/IAE.0000000000003472
pii: 00006982-202207000-00021
pmc: PMC9200227
doi:
Substances chimiques
Pyrimidines
0
Fluocinolone Acetonide
0CD5FD6S2M
2,4-diamino-5-cyclohexyl-6-methylpyrimidine
37033-21-9
fluocinolone
CT1IX58L9S
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1392-1398Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc.
Références
Chu CJ, Johnston RL, Buscombe C, et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology 2016;123:316–323.
Han JV, Patel DV, Squirrell D, McGhee CN. Cystoid macular oedema following cataract surgery: a review. Clin Exp Ophthalmol 2019;47:346–356.
Freissinger S, Vounotrypidis E, Wolf A, et al. Evaluation of functional outcomes and OCT-biomarkers after intravitreal dexamethasone implant for postoperative cystoid macular edema in vitrectomized eyes. J Ophthalmol 2020;2020:3946531.
Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in Patientts with chronic diabetic macular edema. Ophthalmology 2014;121:1892–1903.
Mayer WJ, Kurz S, Wolf A, et al. Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome. J Cataract Refract Surg 2015;41:1954–1961.
Hattenbach LO, Springer-Wanner C, Hoerauf H, et al. Intravitreal sustained-release steroid implants for the treatment of macular edema following surgical removal of epiretinal membranes. Ophthalmologica 2017;237:232–237.
Rahimy E, Khurana RN. Anterior segment migration of dexamethasone implant: risk factors, complications, and management. Curr Opin Ophthalmol 2017;28:246–251.
Papastavrou VT, Zambarakji H, Dooley I, et al. Observation: fluocinolone acetonide (Iluvien) implant migration in to the anterior chamber. Retin Cases Brief Rep 2017;11:44–46.
Mateo C, Alkabes M, Burés-Jelstrup A. Scleral fixation of dexamethasone intravitreal implant (OZURDEX®) in a case of angle-supported lens implantation. Int Ophthalmol 2014;34:661–665.
Herold TR, Liegl R, Koenig S, et al. Scleral fixation of the fluocinolone acetonide implant in eyes with severe iris-lens diaphragm disruption and recalcitrant CME: the fluocinolone-loop-anchoring technique (FLAT). Ophthalmol Ther 2020;9:175–179.
Rezaei K, Tabandeh H. Scleral fixation of fluocinolone acetonide implant. Am J Ophthalmol Case Rep 2020;19:100775.
Cicinelli MV, Rosenblatt A, Grosso D, et al. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular edema. Eye (Lond) 2021;35:3459.
Rosenblatt A, Udaondo P, Cunha-Vaz J, et al. A collaborative retrospective study on the efficacy and safety of intravitreal dexamethasone implant (ozurdex) in patientts with diabetic macular edema: the European DME registry study. Ophthalmology 2020;127:377–393.
Riemann CD, Eaton AM, Cutino A, Cutino A. Reduction in retinal thickness fluctuations after treatment with fluocinolone acetonide implant for DME: a post-hoc analysis of the user study. Ophthalmic Surg Lasers Imaging Retina 2020;51:298–306.